Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297026 | 0.86 | HDAC6 (0.47) | ALDH1A1KDM4EALOX15HSD17B10HDAC6 | |
| SCHEMBL16624609 | 0.85 | HDAC6 (0.57) | ALDH1A1KDM4EALOX15HSD17B10HDAC6 | |
| SCHEMBL18294907 | 0.85 | HDAC6 (0.51) | ALDH1A1KDM4EALOX15HSD17B10HDAC6 | |
| SCHEMBL21943233 | 0.85 | HDAC6 (0.51) | ALDH1A1KDM4EALOX15HSD17B10HDAC6 | |
| SCHEMBL24488778 | 0.84 | HDAC6 (0.58) | ALDH1A1KDM4EALOX15HSD17B10HDAC6 | |
| SCHEMBL19267854 | 0.81 | HDAC6 (0.58) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL6881495 | 0.79 | P2RY12 (0.49) | ALDH1A1HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL11562123 | 0.78 | HCAR3 (0.57) | ALDH1A1HSD17B10MGAMLDHAP4HA1 | |
| SCHEMBL19267853 | 0.77 | HDAC6 (0.54) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL18542037 | 0.76 | TDP1 (0.57) | ALDH1A1KDM4EHDAC6HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3468559-B1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230190744-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8148526-B1 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148526-B1 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | ALDH1A1 2570/4885KDM4E 1559/4885ALOX15 4661/4885 |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | HDAC5, HDAC6, HDAC9 | ALDH1A1 1018/4885KDM4E 66/4885ALOX15 4791/4885 |
| US-11813261-B2 | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia | BTK, HDAC2, HDAC4 | ALDH1A1 3843/4885KDM4E 246/4885ALOX15 3229/4885 |
| US-20230190744-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF | HDAC1, HDAC3, HDAC8 | ALDH1A1 791/4885KDM4E 416/4885ALOX15 3773/4885 |
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | BCL2, HDAC1, HDAC3 | ALDH1A1 2067/4885KDM4E 1021/4885ALOX15 4234/4885 |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | ALDH1A1 2570/4885KDM4E 1559/4885ALOX15 4661/4885 |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | ALDH1A1 2570/4885KDM4E 1559/4885ALOX15 4661/4885 |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | HDAC1, HDAC3, HDAC8 | ALDH1A1 2993/4885KDM4E 741/4885ALOX15 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.